Replies to post #142 on Alkermes, Inc. (ALKS)

[surf1944]

7:05AM Alkermes receives Fast Track Designation for ALKS 5461 for major depressive disorder (ALKS) 30.17 : Co announced that the FDA has granted Fast Track status for ALKS 5461 for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard therapies. Fast Track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and with the potential to address an unmet medical need.